PMID: 8581559Sep 1, 1995Paper

An endogenous dopaminergic neurotoxin: implication for Parkinson's disease

Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration
M B MattammalR Strong

Abstract

Oxidation of dopamine by monoamine oxidase results in the endogenous metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). The toxicity of DOPAL for dopaminergic neurons was investigated using rat neostriatal synaptosomes, PC-12 cells and cultures of fetal rat dissociated mesencephalon. The Na(+)-dependent uptake of [3H]DOPAL in synaptosomes was inhibited by mazindol. DOPAL selectively inhibited dopamine uptake but not [14C]GABA uptake, induced membrane damage and liberation of dopamine into the medium. Incubation of PC-12 cells with 6.5 microM of DOPAL for 24 h caused degeneration of the neuritic process, and the number of viable cells were reduced by 25% of control. There were practically no surviving cells after 24 h of incubation with 33 microM of DOPAL. After 8 h of treatment with 33 microM of DOPAL, dopamine and 3,4-dihydroxyphenylacetic acid content in the cells were reduced by 38% and 53% of control. DOPAL-induced cell damage released lactic acid dehydrogenase into the incubation media. This toxic effect of DOPAL was time- and concentration-dependent. In mesencephalic cultures, after exposure to 33 microM of DOPAL, the surviving TH+ cells showed rounded cell body, and fibre network was highly reduced. These results indica...Continue Reading

References

Jul 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·L A Greene, A S Tischler
Oct 1, 1991·Brain : a Journal of Neurology·J M Fearnley, A J Lees
Jan 1, 1989·Progress in Neuro-psychopharmacology & Biological Psychiatry·O Hornykiewicz

❮ Previous
Next ❯

Citations

Jul 26, 2003·Antioxidants & Redox Signaling·Sushil K Sharma, Manuchair Ebadi
May 14, 2005·Antioxidants & Redox Signaling·April A DukesTeresa G Hastings
Feb 10, 2016·Environmental Science and Pollution Research International·Yufei HuJun He
Aug 18, 2004·Annales pharmaceutiques françaises·J-J BonnetJ Costentin
Aug 17, 2010·Pharmacology & Therapeutics·Megan J DowieMichelle Glass
May 8, 2007·Journal of Dermatological Science·Eun-Sang ParkKyoung-Chan Park
Jun 22, 2013·Journal of Neurochemistry·David S GoldsteinYehonatan Sharabi
Dec 12, 2012·Annals of Neurology·Anthony DonsanteStephen G Kaler
Nov 16, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·D S GoldsteinD C Mash
Oct 24, 2000·Japanese Journal of Pharmacology·S V YimJ H Chung
Dec 26, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tzu-Yun WangRu-Band Lu
Jan 21, 2015·Toxicological Sciences : an Official Journal of the Society of Toxicology·Chelsea T TiernanKeith J Lookingland
Sep 25, 2007·Chemical Research in Toxicology·Jennifer N ReesJonathan A Doorn
Aug 16, 2016·The European Journal of Neuroscience·Kelly M LohrGary W Miller
Jul 7, 2006·Cellular and Molecular Neurobiology·Toshi Nagatsu, Makoto Sawada
Mar 5, 2009·Molecular Neurobiology·Thomas S Guillot, Gary W Miller
Jan 17, 2019·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·David S Goldstein
Apr 22, 1997·Proceedings. Biological Sciences·J Smythies
Apr 28, 2018·The Journal of Pharmacology and Experimental Therapeutics·Yunden JinsmaaDavid S Goldstein
Aug 20, 2004·Pharmacological Reviews·Graeme EisenhoferDavid S Goldstein
Jul 2, 2019·Central Nervous System Agents in Medicinal Chemistry·Idalet EngelbrechtAnél Petzer
Dec 7, 2019·Journal of Neural Transmission·David S Goldstein
Mar 9, 2010·Clinical Chemistry·Courtney HolmesDavid S Goldstein
Nov 21, 2019·The Journal of Pharmacology and Experimental Therapeutics·Yunden JinsmaaDavid S Goldstein
Jun 28, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·C PiflO Hornykiewicz
Sep 7, 2019·Molecular Neurodegeneration·Anna MasatoLuigi Bubacco
Mar 16, 2017·Acta Neuropathologica Communications·Francesco LongoMichele Morari
Dec 14, 2019·Scientific Reports·Chia-Yen LinChun-Hsiang Tan
Mar 23, 2017·Pathobiology of Aging & Age Related Diseases·Xiang BaiRandy Strong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.